Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights
Provided By GlobeNewswire
Last update: Aug 5, 2025
Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD
SOL-1 remains on track for 1Q 2026 topline data
Read more at globenewswire.comNASDAQ:OCUL (8/27/2025, 11:51:28 AM)
12.35
+0.03 (+0.24%)
Find more stocks in the Stock Screener
